While transitioning from insulin to GLP-1/GIP receptor agonists (e.g., tirzepatide, semaglutide, dulaglutide) offers benefits such as improved glycemic control, weight loss, and reduced hypoglycemia risk, some complications can arise during the switch, as shown in Table 3. The gene discussed is GLP1R; the disease is Hypoglycemia.